> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Just-Posted CRL Cites China-Heavy Trial Data in Ivonescimab Rejection
- URL: https://www.fdaweb.com/fda-cites-china-heavy-trial-data-in-summit-ivonescimab-rejection/
- Published: 2026-11-17T23:13:48.000Z
- Updated: 2026-11-17T23:14:45.000Z
- Author: David McFarland
- Tags: Drugs

FDA's just-posted [complete response letter](https://download.open.fda.gov/crl/CRL%5FBLA761524%5F20261113.pdf?ref=fdaweb.com) to Summit Therapeutics reveals that concerns about the geographic composition of the company's pivotal HARMONi trial contributed to the agency's rejection of ivonescimab for lung cancer, beyond the previously disclosed failure to demonstrate a statistically significant overall survival benefit.

In the 11/13 letter, FDA said 93% of progression-free survival (PFS) events — 257 of 275 — occurred among patients enrolled in China, preventing the agency from establishing whether the trial's positive PFS results were applicable to the U.S. population.

FDA said it had raised concerns about the enrollment strategy during a 3/2023 Type A meeting and reiterated them at a 5/2025 pre-BLA meeting.

The trial initially enrolled patients exclusively in China, where approximately 60% of the study population entered between January and November 2022\. Enrollment in North America and Europe did not begin until May 2023.

As [previously reported by ***FDA Webview***](https://www.fdaweb.com/fda-denies-approval-to-summit-bla-for-lung-cancer/), FDA rejected Summit's BLA for ivonescimab plus platinum-containing chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer previously treated with an EGFR tyrosine kinase inhibitor.

Although HARMONi demonstrated a statistically significant PFS benefit, FDA characterized the improvement in median PFS as modest, citing the absence of a statistically significant overall survival benefit and no substantial difference in overall response rate.

The agency also rejected reliance on subsequent post-hoc survival analyses, calling them exploratory and noting that different data cutoff dates across geographic regions further limited their interpretation. Chinese clinical sites had closed during 2025, ending follow-up earlier than at North American and European sites.

FDA concluded that the PFS benefit did not outweigh additional toxicities associated with ivonescimab, including serious immune-related adverse effects and toxicities associated with VEGF inhibition.

The agency recommended a new adequate and well-controlled multiregional clinical trial, consistent with ICH E17, demonstrating a statistically significant and clinically meaningful improvement in overall survival, PFS or another clinical-benefit endpoint sufficient to outweigh the drug's toxicity.

FDA also recommended that Summit meet with the agency before initiating the trial to discuss its design and endpoints.